IP Library Granted Patent US 7,205,337
Granted Patent B2
US 7,205,337 · App. 10/600,130 · Granted Apr 17, 2007

End-capped polymers and compositions containing such compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,205,337
App. No.
10/600,130
Granted
Apr 17, 2007
Kind
B2
Abstract

End-capped polymers, methods for making those end-capped polymers, compositions containing those end-capped polymers, and methods for using those compositions are disclosed. One of the disclosed end-capped copolymers has the formula (I): and may be combined with natural or synthetic bone minerals, bone tissue, collagen tissue, bone protein or combinations or derivatives of those materials to form a tissue repair composition.

Claims (48)

1. A composition comprising: (i) a soluble product extracted from demineralized bone and (ii) a carrier comprising a polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer wherein both terminal hydroxyl groups in the triblock copolymer have been replaced with terminal methoxy groups and wherein the polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer is derived from a dilithium salt of a dihydroxy starting material, and wherein the compound has no hydroxyl groups.

2. The composition according to claim 1 , wherein the carrier further comprises a solvent.

3. The composition according to claim 2 , wherein the solvent is water.

4. The composition according to claim 3 , wherein the carrier comprises about 25% to about 30% weight of the compound according to formula (I) and about 75% to about 70% weight water.

5. The composition according to claim 1 , wherein the degree of polymerization of the polyoxyproplylene block is about 101 and the degree of polymerization of both polyoxyethylene blocks is about 56″ therefor.

6. The composition according to claim 4 , wherein the carrier exhibits reverse phase behavior.

7. The composition according to claim 1 , wherein the soluble product is about 20% to about 80% weight of the composition and the carrier is about 80% to 20% weight of the composition.

8. The composition according to claim 7 , wherein the soluble product is about 60% weight of the composition and the carrier is about 40% weight of the composition.

9. The composition according to claim 1 , further comprising an insoluble product extracted from demineralized bone.

10. The composition according to claim 9 , wherein the soluble product is about 1% to about 80% weight of the composition, the carrier is about 10% to about 40% weight of the composition, and the insoluble product is about 20% to about 50% weight of the composition.

11. The composition according to claim 10 , wherein the soluble product is about 30% to about 40% weight of the composition, the carrier is about 26% to about 28% weight of the composition, and the insoluble product is about 30% weight of the composition.

12. The composition according to claim 9 , further comprising demineralized bone.

13. The composition according to claim 12 , wherein the demineralized bone is in the form of a powder.

14. The composition according to claim 13 , wherein the soluble product is about 1% to about 20% weight of the composition, the carrier is about 10% to about 40% weight of the composition, the insoluble product is about 0.1% to about 15% weight of the composition, and the demineralized bone powder is about 10% to about 40% weight of the composition.

15. The composition according to claim 14 , wherein the soluble product is about 3% to about 5% weight of the composition, the carrier is about 26% to about 28% weight of the composition, the insoluble product is about 6% to about 9% weight of the composition, and the demineralized bone powder is about 23% to about 27% weight of the composition.

16. The composition according to claim 1 , further comprising bone chips.

17. The composition according to claim 16 , wherein the bone chips are about 1% to about 20% weight of the composition.

18. The composition according to claim 9 , further comprising bone chips.

19. The composition according to claim 18 , wherein the bone chips are about 1% to about 20% weight of the composition.

20. The composition of claim 9 , further comprising at least one of hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate or calcium sulfate.

21. The composition according to claim 12 , further comprising at least one of hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate or calcium sulfate.

22. The composition according to claim 21 , wherein the at least one of hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate or calcium sulfate is about 15% to about 30% weight of the composition.

23. The composition according to claim 16 , further comprising at least one of hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate or calcium sulfate.

24. The composition according to claim 18 , further comprising at least one of hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate or calcium sulfate.

25. A composition comprising (i) at least one material of demineralized bone powder, bone chips, insoluble product, hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate, or calcium sulfate, wherein the material is coated by a soluble product extracted from demineralized bone and (ii) a carrier comprising a polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer wherein both terminal hydroxyl groups in the triblock copolymer have been replaced with terminal methoxy groups.

26. The composition according to claim 25 , wherein the at least one coated material of demineralized bone powder, bone chips, insoluble product, hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate, or calcium sulfate is about 30% to about 70% weight of the composition, the soluble product is about 5% to about 20% weight of the composition and the carrier is about 10% to about 40% weight of the composition.

27. The composition according to claim 25 , wherein the composition comprises hydroxylapatite.

28. The composition according to claim 27 , wherein the hydroxylapatite has been treated with a poreformer.

29. The composition according to claim 27 , wherein the hydroxylapatite is derived from bone.

30. The composition according to claim 27 , wherein the hydroxylapatite has been treated with a binder.

31. The composition according to claims 25 , wherein the composition comprises a combination of hydroxylapatite and tricalcium phosphate.

32. The composition according to claim 31 , wherein the hydroxylapatite is about 60% to about 80% weight of the combination and the tricalcium phosphate is about 20% to about 40% of the combination.

33. The composition according to claim 25 , wherein the particle size of the demineralized bone powder and the insoluble product is between about 10 to about 1,000 microns.

34. The composition according to claim 33 , wherein the particle size of the demineralized bone powder and the insoluble product is between about 125 to about 500 microns.

35. The composition according to claim 25 , wherein the particle size of the bone chips, hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate, and calcium sulfate is between about 100 to about 7,000 microns.

36. The composition according to claim 35 , wherein the particle size of the bone chips, hydroxylapatite, tricalcium phosphate, biphasic calcium phosphate, and calcium sulfate is between about 1,000 to about 4,000 microns.

37. A method of treating tissue comprising applying a composition of claim 1 to a tissue.

38. The method of claim 37 , wherein the tissue is a bone defect site.

39. A method of treating tissue comprising applying a composition of claim 25 to a tissue.

40. The method of claim 39 , wherein the tissue is a bone defect site.

41. A composition comprising: (i) an osteogenic agent and (ii) a carrier comprising a polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer wherein both terminal hydroxyl groups in the triblock copolymer have been replaced with terminal methoxy groups and wherein the polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer is derived from a dilithium salt of a dihydroxy starting material, and wherein the compound has no hydroxyl groups.

42. The composition according to claim 41 , wherein the carrier further comprises a solvent.

43. The composition according to claim 42 , wherein the solvent is water.

44. The composition according to claim 43 , wherein the carrier comprises about 25% to about 30% weight of the compound according to formula (I) and about 75% to about 70% weight water.

45. The composition according to claim 41 , wherein a is about 101 and b is about 56.

46. The composition according to claim 43 , wherein the carrier exhibits reverse phase behavior.

47. The composition of claim 41 , wherein the osteogenic agent is a protein.

48. The composition of claim 47 , wherein the osteogenic agent is a protein that enhances the repair of a bone defect.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 7, 2024
From: JPMORGAN CHASE BANK, N.A.
To: SEASPINE ORTHOPEDICS CORPORATION; SEASPINE, INC.; ISOTIS ORTHOBIOLOGICS, INC.; THEKEN SPINE, LLC
Reel/Frame 069323/0561 →
SECURITY INTEREST Recorded Feb 21, 2023
From: SEASPINE ORTHOPEDICS CORPORATION; SEASPINE, INC.; ISOTIS ORTHOBIOLOGICS, INC.; THEKEN SPINE, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE ASSISTANT
Reel/Frame 062819/0650 →
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2023
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: SEASPINE HOLDINGS CORPORATION; SEASPINE ORTHOPEDICS CORPORATION; SEASPINE, INC.; ISOTIS, INC.; SEASPINE SALES LLC; ISOTIS ORTHOBIOLOGICS, INC.; THEKEN SPINE, LLC; SEASPINE ORTHOPEDICS INTERMEDIATECO, INC.; 7D SURGICAL USA INC.
Reel/Frame 062336/0593 →
SECOND AMENDMENT TO PATENT SECURITY AGREEMENT Recorded Jul 18, 2022
From: SEASPINE HOLDINGS CORPORATION; SEASPINE ORTHOPEDICS CORPORATION; SEASPINE, INC.; ISOTIS, INC.; SEASPINE SALES LLC; ISOTIS ORTHOBIOLOGICS, INC.; THEKEN SPINE, LLC; SEASPINE ORTHOPEDICS INTERMEDIATECO, INC.; 7D SURGICAL USA INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 060715/0395 →
SECURITY INTEREST Recorded Dec 28, 2015
From: SEASPINE HOLDINGS CORPORATION; SEASPINE ORTHOPEDICS CORPORATION; SEASPINE, INC.; ISOTIS, INC.; SEASPINE SALES LLC; ISOTIS ORTHOBIOLOGICS, INC.; THEKEN SPINE, LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037393/0895 →